Los Angeles, California 90095

  • Prostate Cancer


RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase III trial to determine the effectiveness of atrasentan in treating patients who have prostate cancer that has not responded to hormone therapy.

Study summary:

OBJECTIVES: - Determine the safety of atrasentan in patients with hormone-refractory prostate cancer. - Determine the pharmacokinetics of this drug in these patients. OUTLINE: This is an open-label, multicenter study. Patients receive oral atrasentan once daily for 3 years in the absence of disease progression or unacceptable toxicity. Patients are followed at 1 month and then every 3 months for 2 years. PROJECTED ACCRUAL: Approximately 1,400 patients will be accrued for this study.


DISEASE CHARACTERISTICS: - Diagnosis of hormone-refractory prostate cancer - Completed protocol ABBOTT-M00-211 or ABBOTT-M00-244 within the past 30 days - Disease progression OR - Active in trial when double-blind treatment period ended PATIENT CHARACTERISTICS: Age - 19 and over Performance status - Karnofsky 60-100% Life expectancy - Not specified Hematopoietic - WBC at least 3,000/mm3 - Absolute neutrophil count greater than 1,000/mm3 - Platelet count at least 100,000/mm3 - Hemoglobin at least 9 g/dL Hepatic - Bilirubin less than 1.5 mg/dL - AST and ALT no greater than 1.5 times upper limit of normal Renal - Creatinine clearance at least 40 mL/min Cardiovascular - No New York Heart Association class II-IV heart disease Pulmonary - No significant pulmonary disease requiring chronic or pulse steroid therapy within the past 3 months Other - Fertile patients must use 2 effective methods of contraception (1 must be barrier contraception) during and for 8 weeks after study - No reason that would preclude study - No significant comorbid condition that would preclude study PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - At least 4 weeks since other prior cytotoxic chemotherapy - No other concurrent cytotoxic chemotherapy Endocrine therapy - Not specified Radiotherapy - At least 4 weeks since prior radionuclides - No concurrent radionuclides Surgery - Not specified Other - At least 4 weeks since prior investigational agents - No concurrent antiretroviral therapy for HIV-positive patients - No concurrent participation in another investigational study



Primary Contact:

Gary Gordon, MD, PhD

Backup Contact:


Location Contact:

Los Angeles, California 90095
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.